{"legislative_session": "2026", "identifier": "HB314", "title": "Ibogaine; authorize SDH to select a consortium to conduct a drug development clinical trial with, to secure FDA's approval of.", "from_organization": "~{\"classification\": \"lower\"}", "classification": ["bill"], "subject": ["Public Health and Human Services"], "abstracts": [], "other_titles": [], "other_identifiers": [], "actions": [{"description": "Referred To Public Health and Human Services", "date": "2026-01-08T06:00:00+00:00", "organization_id": "~{\"classification\": \"lower\"}", "classification": ["referral-committee"], "related_entities": []}, {"description": "Title Suff Do Pass", "date": "2026-01-20T06:00:00+00:00", "organization_id": "~{\"classification\": \"lower\"}", "classification": ["committee-passage"], "related_entities": []}, {"description": "Passed", "date": "2026-01-21T06:00:00+00:00", "organization_id": "~{\"classification\": \"lower\"}", "classification": ["passage"], "related_entities": []}, {"description": "Transmitted To Senate", "date": "2026-01-27T06:00:00+00:00", "organization_id": "~{\"classification\": \"lower\"}", "classification": ["introduction"], "related_entities": []}], "sponsorships": [{"name": "Creekmore", "classification": "primary", "entity_type": "person", "primary": true, "person_id": "~{\"name\": \"Creekmore\"}", "organization_id": null}, {"name": "Arnold", "classification": "cosponsor", "entity_type": "person", "primary": false, "person_id": "~{\"name\": \"Arnold\"}", "organization_id": null}, {"name": "Carpenter", "classification": "cosponsor", "entity_type": "person", "primary": false, "person_id": "~{\"name\": \"Carpenter\"}", "organization_id": null}], "related_bills": [], "versions": [{"note": "Current version", "links": [{"url": "http://billstatus.ls.state.ms.us/documents/2026/html/HB/0300-0399/HB0314PS.htm", "media_type": "text/html"}, {"url": "http://billstatus.ls.state.ms.us/documents/2026/pdf/HB/0300-0399/HB0314PS.pdf", "media_type": "application/pdf"}], "date": "", "classification": ""}, {"note": "As Introduced", "links": [{"url": "http://billstatus.ls.state.ms.us/documents/2026/html/HB/0300-0399/HB0314IN.htm", "media_type": "text/html"}, {"url": "http://billstatus.ls.state.ms.us/documents/2026/pdf/HB/0300-0399/HB0314IN.pdf", "media_type": "application/pdf"}], "date": "", "classification": ""}], "documents": [], "citations": [], "sources": [{"url": "https://billstatus.ls.state.ms.us/documents/2026/pdf/HB/0300-0399/HB0314PS.pdf", "note": ""}, {"url": "http://billstatus.ls.state.ms.us/2026/pdf/House_authors/Creekmore_IV.xml", "note": ""}, {"url": "http://billstatus.ls.state.ms.us/2026/pdf/House_authors/Arnold.xml", "note": ""}, {"url": "http://billstatus.ls.state.ms.us/2026/pdf/House_authors/Carpenter.xml", "note": ""}, {"url": "https://billstatus.ls.state.ms.us/2026/pdf/history/HB/HB0314.xml", "note": ""}], "extras": {"summary": "AN ACT TO BE KNOWN AS THE IBOGAINE DRUG DEVELOPMENT CLINICAL TRIAL ACT; TO AUTHORIZE THE ESTABLISHMENT OF A CONSORTIUM TO APPLY FOR SELECTION BY THE STATE DEPARTMENT OF HEALTH TO CONDUCT A DRUG DEVELOPMENT CLINICAL TRIAL WITH IBOGAINE AND SECURE THE UNITED STATES FOOD AND DRUG ADMINISTRATION'S (FDA) APPROVAL OF IBOGAINE AS A MEDICATION FOR THE TREATMENT OF OPIOID USE DISORDER, CO-OCCURRING SUBSTANCE USE DISORDER, AND ANY OTHER NEUROLOGICAL OR MENTAL HEALTH CONDITION FOR WHICH IBOGAINE DEMONSTRATES EFFICACY; TO REQUIRE THE CONSORTIUM TO SUBMIT TO THE DEPARTMENT A PROPOSAL FOR PURPOSES OF CONDUCTING AN IBOGAINE DRUG DEVELOPMENT CLINICAL TRIAL, AND SPECIFY WHAT THE PROPOSAL MUST INCLUDE; TO PROVIDE THAT AFTER SELECTING A CONSORTIUM, THE DEPARTMENT SHALL ENTER INTO AN INTERAGENCY CONTRACT WITH THE CONSORTIUM TO PROVIDE FUNDING TO IMPLEMENT THE CONSORTIUM'S PROPOSED IBOGAINE DRUG DEVELOPMENT CLINICAL TRIAL; TO SPECIFY WHAT THE INTERAGENCY CONTRACT MUST INCLUDE; TO PROVIDE THAT THE DEPARTMENT MAY NOT DISBURSE FUNDS TO OR FOR A SELECTED CONSORTIUM UNDER THE INTERAGENCY CONTRACT UNTIL THE CONSORTIUM RECEIVES AND THE DEPARTMENT VERIFIES THE RECEIPT OF MATCHING FUNDS FROM SOURCES OTHER THAN THE STATE; TO REQUIRE THE SELECTED CONSORTIUM TO SUBMIT AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION WITH THE FDA AND SEEK A BREAKTHROUGH THERAPY DESIGNATION FOR IBOGAINE FROM THE FDA; TO REQUIRE THE SELECTED CONSORTIUM TO ENTER INTO AN AGREEMENT WITH A CONSORTIUM ESTABLISHED BY THE GOVERNMENT OF ANOTHER STATE THAT HAS SUBMITTED AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO THE FDA AND HAS REQUESTED A BREAKTHROUGH THERAPY DESIGNATION FOR IBOGAINE FROM THE FDA; TO REQUIRE THE SELECTED CONSORTIUM TO WORK WITH THE FDA TO COORDINATE THE DRUG DEVELOPMENT TRIAL IN MISSISSIPPI WITH IBOGAINE DRUG DEVELOPMENT TRIALS THAT ARE BEING CONDUCTED IN OTHER STATES; TO PROVIDE THAT ONLY AN INSTITUTION OF HIGHER LEARNING OR A HOSPITAL MAY SERVE AS A TRIAL SITE FOR CONDUCTING AN IBOGAINE DRUG DEVELOPMENT CLINICAL TRIAL; TO PROVIDE FOR ALLOCATION OF THE REVENUE ATTRIBUTABLE TO ALL INTELLECTUAL PROPERTY RIGHTS AND OTHER COMMERCIAL RIGHTS ARISING FROM THE DRUG DEVELOPMENT CLINICAL TRIAL CONDUCTED BY A CONSORTIUM DURING THE PERIOD FOR WHICH THE TRIAL IS FUNDED AND ANY FOLLOWING PERIOD OF COMMERCIALIZATION; TO PROVIDE THAT IF IBOGAINE IS APPROVED BY THE FDA TO TREAT A MEDICAL CONDITION, A PHYSICIAN WHO HAS PRESCRIBED IBOGAINE FOR A PATIENT SHALL SUPERVISE THE ADMINISTRATION OF IBOGAINE AT A HOSPITAL OR OTHER LICENSED HEALTH CARE FACILITY TO ENSURE THE PATIENT'S SAFETY WHILE THE PATIENT IS UNDER THE INFLUENCE OF IBOGAINE; AND FOR RELATED PURPOSES."}, "jurisdiction": {"id": "ocd-jurisdiction/country:us/state:ms/government", "name": "Mississippi", "classification": "state", "division_id": "ocd-division/country:us/state:ms"}, "scraped_at": "2026-02-10T08:56:51+00:00", "_id": "709e918a-065e-11f1-add7-b2a955b1c39c"}